Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program. (PubMed, Int J Clin Oncol) - Sep 25, 2026 - P=N/A | "This study provides additional prospective evidence consistent with the preceding NivoCUP trial, supporting the reproducibility of the efficacy and safety of nivolumab for patients with CUP. These findings support PD-1-targeted therapy as a feasible treatment option for this rare malignancy."
Biomarker • IO biomarker • Journal • Oncology • PD-L1
|
|
Akihiko Ito; Hidetoshi Hayashi; Hiroko Watanabe; Hironobu Minami; Junko Tanizaki; Kan Yonemori; Kazuhiko Nakagawa; Kazuko Sakai; Kazunori Honda; Kazuto Nishio; Keigo Komine; Kenro Hirata; Kohei Akiyoshi; Koichi Suyama; Mariko Sato; Ryotaro Ohkuma; Takuma Onoe; Yasutaka Chiba; Yosuke Horita; Yosuke Togashi; Yuichi Takiguchi; Yusuke Onozawa
|